# Zoetis share price today (Zoetis Inc., ZTS)

> Zoetis Inc.'s P/E is near the low end of its own history, higher than only 10% of past readings, and its quarterly results are still getting worse. ZTS · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/zts

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: $82.99 (−42.4% in a year)
- P/E: 13.5× (lower than 90% of the last 4.6 years)
- Revenue (Jun 2026): $2.5 B (−0.2% on a year ago)
- Profit (Jun 2026): $691 M (−4.8% on a year ago)
- Operating margin: 40.7% (flat on a year ago)
- ROE: 80%, FY25
- ROIC: 27.3%, against a 7.0% cost of capital: +20.3 points

The main question: yearly earnings per share moved +10.1% while the share price moved −42.4%. ## What is the Zoetis share price today? Zoetis Inc.'s share price was $82.99 at the close on 3 November 2026. It has been falling for 86 weeks. That is 10.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $70 and $131, and at that close it sat 22% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 10 years the share price moved +71% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Zoetis pay? Zoetis Inc. paid $2.06 per share over the last four reported quarters. The most recent declaration was $0.53 for Jun 2026. At today's price of $82.99 that is a yield of 2.48%, based on dividends already paid, not a forecast. ## Which stock lists is Zoetis on? Zoetis is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Zoetis profitable? Zoetis Inc. earned $691 M of net profit in the Jun 2026 quarter, −4.8% on the same quarter a year earlier. Full-year FY25 profit was $2.7 B. Over 4 years profit has grown 7.0% a year on average. That is 28.0% of the quarter's revenue. The same quarter a year earlier earned $726 M. For the full year, FY25 profit was $2.7 B (+7.5% on the year before). Why profit moved: revenue changed −0.2% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +1.1% and revenue +1.6%. Profit and revenue are moving at about the same pace. ## How much revenue does Zoetis make, and is it growing? Zoetis Inc. reported $2.5 B of revenue in the Jun 2026 quarter, −0.2% on the same quarter a year earlier. Over 4 years it has grown 5.0% a year on average. The last full year, FY25, came in at $9.5 B. The last four reported quarters add to $9.5 B. FY25 revenue was $9.5 B, +2.3% on the year before. Recent pace: the last four quarters grew +1.6% on average, against 5.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.5%, against +3.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +1.0%, against +5.6% a year (rolling over). ## How much of every $100 of sales does Zoetis keep? Zoetis Inc.'s operating margin was 40.7% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 35.9% and 38.3%. The latest quarter is above every full year in that period. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Across 5 years it has been between 35.9% and 38.3%, and FY25's 38.3% is the highest of them. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed −0.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Zoetis' profit turning into cash? Over the last 3 years, 109% of Zoetis Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $2.9 B of operating cash against $2.7 B of profit. After $621 M of spending on assets, $2.3 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Zoetis' cash go? Zoetis Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.0 B on assets over the last 3 years. Averaged over those years that is 7.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.0 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Zoetis' P/E ratio, and how does it compare with its own history? Zoetis Inc.'s P/E is 13.5×, near the low end of its own history: it has been lower only 10% of the time. Its usual P/E (the middle reading) is 33.3×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +10.1% while the price moved −42.4%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −20.0% a year; about +7.3% a year came from earnings growth and about −27.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Zoetis business getting better or worse? Zoetis Inc.'s business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 29.9%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Zoetis earn on its capital? Zoetis Inc. earned a ROE of 80% in FY25. That is up from a low of 45% in FY21. Its return on capital used (ROIC) is 20.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 28.2% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 28.2% net margin × 0.61× asset turnover × 4.64× leverage (assets divided by equity) ≈ 79.8% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 27.3% − 7.0% = +20.3 percentage points. The 7.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 27.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 28.9%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Zoetis have too much debt? Zoetis Inc. has total debt of $9.3 B against shareholder equity of $3.1 B as of Jun 2026, so its debt is 2.94× its equity. Year by year, that ratio went from 1.49 in FY21 to 2.80 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Zoetis shareholding pattern? 4.3% of Zoetis Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Zoetis from balance-sheet trouble? For Zoetis Inc., the Z-score is 5.87. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.87 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Zoetis rank in its industry? 46.8 out of 100, rank 16 of 28 in Drug Manufacturers - Specialty & Generic, with 81% of the evidence available. Zoetis Inc. scores 46.8 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.1 + 20.4 + 8.3 + 6 = 46.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Zoetis compared with? Zoetis ranks 16 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 46.8 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. Zoetis Inc. this page ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.1/35 · Revenue 1.5% · Profit 1% · Operating margin change 0 points · 83% evidence Capital efficiency 20.4/25 · ROCE 27.7% · Operating margin 40.7% · 76% evidence Valuation 8.3/20 · P/E 11.5× · PEG 2.14 · 65% evidence Relative strength 6.0/20 · Lead over its industry -30.1% · Lead over S&P 500 -20.8% · 1 year -31% · 100% evidence · 1 of 12 weeks ahead Exact sum: 12.1 + 20.4 + 8.3 + 6 = 46.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Zoetis in size? Zoetis is the 4th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Takeda Pharmaceutical Company, Teva Pharmaceutical Industries and Haleon plc. Just below it: United Therapeutics Corporation, Viatris Inc. and Neurocrine Biosciences, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Takeda Pharmaceutical Company Limited](https://www.sectoralpha.in/us/stocks/tak) $67.3 billion
2. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) $48.8 billion
3. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) $38.8 billion
4. Zoetis Inc. $34.3 billion
5. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) $25.8 billion
6. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) $21.7 billion
7. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) $16.8 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Axon Enterprise, Inc.](https://www.sectoralpha.in/us/stocks/axon) $34.6 billion · Aerospace & Defense
2. [The Hershey Company](https://www.sectoralpha.in/us/stocks/hsy) $34.4 billion · Confectioners
3. Zoetis Inc. $34.4 billion
4. [Sunbelt Rentals Holdings, Inc.](https://www.sectoralpha.in/us/stocks/sunb) $34.3 billion · Rental & Leasing Services
5. [EQT Corporation](https://www.sectoralpha.in/us/stocks/eqt) $34.3 billion · Oil & Gas Exploration & Production

## What else do people ask about Zoetis? ### What were Zoetis's latest quarterly results? Zoetis Inc. reported revenue of $2.5 B and net profit of $691 M for the Jun 2026 quarter. Revenue fell 0.2% and profit fell 4.8% compared with a year earlier. Earnings per share were $1.65. The operating margin was 40.7%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Zoetis's market cap? Zoetis Inc.'s market capitalisation is $34.3 B at a stock price of $82.99. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Zoetis performing? Zoetis Inc.'s share price has been falling for 86 weeks. In its latest quarter, revenue fell 0.2% and profit fell 4.8% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running (as of 3 November 2026). ### Will Zoetis's stock price go up? This page does not forecast Zoetis Inc.'s stock price. What it shows instead: the stock price is $82.99, and it has been falling for 86 weeks. Its P/E of 13.5× is higher than 10% of its own last 5 years (as of 3 November 2026). ### Where is Zoetis in its business cycle? Zoetis Inc.'s FY25 operating margin was 38.3%, against a 5-year range of 35.9% to 38.3%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 40.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Zoetis story? The main question: yearly earnings per share moved +10.1% while the share price moved −42.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Zoetis a stock worth studying right now? What the numbers show: Zoetis Inc.'s P/E is near the low end of its own history, higher than only 10% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.